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ABSTRACT
Objective: The aim of the present study is to evaluate the efficacy of Vamana karma in the management of dyslipidemia.
Methods: Patients were selected from the OPD and IPD at the Department of Panchakarma, Hospital of Rishikul Campus, Uttarakhand Ayurved 
University, Haridwar. Patients in Group A will be administered with two sittings of Vamana procedure. In Group B, 20 patients will be treated with 
atorvastatin for 60 days in dose of 10 mg once daily after meals with water.
Results: The overall assessment of the therapy was decided on the basis of improvement in biochemical parameter (serum lipid profile) by applying 
statistics. Vamana karma had statistically highly significant result in all the objective parameters except high-density lipoprotein [HDL].
Conclusion: Thus, it can be concluded that dyslipidemia is a form of Kaphavikara specifically may be Medodushti in the form of Abaddha meda. Vamana 
karma is highly effective in correcting serum lipid profile except HDL and very low-density lipoprotein but have better effect than the standard drug 
in both of them. Vamana karma can be used for the effective and safe management of dyslipidemia.
Keywords: Dyslipidemia, Medodushti, Abaddha meda, Kaphavikara, Vamana.
INTRODUCTION
Disorders of lipoprotein metabolism are collectively referred to as 
dyslipidemias [1]. It is an important risk factor in the initiation and 
progression of atherosclerosis and coronary heart disease [2]. The 
association of dyslipidemia with Type 2 diabetes mellitus (DM) as 
comorbidity for cardiovascular events, leading eventually to a high rate 
of mortality, has been a growing concern for the medical fraternity [3]. 
Dyslipidemia is now becoming the cause of most complicated and life-
threatening disorders such as coronary artery disease, ischemic heart 
disease (IHD) (responsible for 56% global IHD) [4], cerebrovascular 
accidents, myocardial infarction (responsible for 18% global 
cardiovascular disease’s) [4], arthritis, and various other disorders like 
hypertension, leading to multiorgan damage [3].
Dyslipidemias are generally characterized clinically by increased plasma 
levels of cholesterol and triglycerides or both, variably accompanied by 
reduced levels of high-density lipoprotein (HDL) cholesterol [1]. It has 
been proved that elevated plasma levels of cholesterol are responsible 
for atherosclerosis in man, and epidemiological data suggest that 
elevated plasma levels of HDL have a protective effect [5]. The majority 
of patients with dyslipidemia have some combination of genetic 
predisposition and environmental contribution [1]. Various allopathic 
drugs are being used for the management of hyperlipidemia. Statins are 
the most effective drugs, possess a very good lipid-lowering action, but 
various serious side effects such as myopathy, rhabdomyolysis, elevation 
in hepatic enzyme levels, memory loss, and mental confusion [6], and 
hence, cannot be continued for a longer duration. Hence, there is need 
to spread Ayurvedic treatment.
In Ayurveda, dyslipidemia is described under various nomenclatures 
such as Medodushti, Atisnigdhadhatu, and Dushit kleda. Dyslipidemia 
is a form of Kaphavikara specifically may be Medodushti in the 
form of Abaddha meda. Abaddha Meda as described by Acharya 
Chakrapani - “Abbadhamitiasahatam” which means the Poshaka 
or Asthayi Medo Dhatu which is mobile in nature and circulates in 
whole body with Rasa-Rakta Dhatu [7]. As per the Ayurveda classics, 
Samshodhana therapy is very effective in treating any disease 
(especially chronic illness), as it eliminates Dosha from the body (root 
of causing disease) [8]. As Acharya Charaka also has clearly mentioned 
Vamana in the treatment of Santarpana Janya Vyadhi [9]. Therefore, 
the current research work was carried out to evaluate the efficacy of 
Vamana Karma in the management of dyslipidemia.
METHODS
The work has been ethically certified by the institutional ethical committee 
(CTRI NO. CTRI/2018/01/011573). Patients were selected from the OPD 
and IPD at the Department of Panchakarma, Hospital of Rishikul Campus, 
Uttarakhand Ayurved University, thereafter the patients were subjected 
for detailed clinical history and physical examination.
Criteria for selection of patients
Inclusion criteria
The following criteria were included in the study:
•	 Patients	between	the	age	group	of	20	and	60	years
•	 NCEP	ATP	III	Guidelines.
S. Cholesterol - >200 mg/dl
S. Triglyceride - >150 mg/dl
S. LDL - >110 mg/dl
S. very low-density lipoprotein (VLDL) -> 41 mg/dl
CHO/HDL Ratio - >4.97 mg/dl




The following criteria were excluded from the study:
•	 Age	<20	years	or	>60	years
•	 Patients	 having	 serious	 cardiac	 ailments	 such	 as	 -	myocardial	
infarction, malignant hypertension, and cardiac failure
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•	 Patients	with	clear	diagnosis	of	DM	Type	I	and	Type	II












These investigations were carried out before, in between, and after 
completion of therapy.
METHODOLOGY FOR GROUP A (VAMANA KARMA)
Procedure of Vamana
All the 20 patients were treated with Vamana karma in two consecutive 
sitting with a gap of 15 days.
Purva Karma
Deepana-pachana
It is carried out with Dravyas having Vayu and Agni predominant 
properties such as Trikatu churna and Panchakola phanta twice in a day 
with lukewarm water.
Snehapana
Achha sneha (Go-Ghrita) according to Koshtha of patient till appearance 
of Samyaka snigdha Lakshana was given for Abhyantara snehapana in 
increasing dose.
Bahya snehana
Bahya Snehana was done with Murchhita Til Taila for 1 day.
Bahya Swedana
Bahya Swedana was carried out with Nadi Swedana.
Pradhana karma
It can be divided into the following steps:
•	 Aakanthapana: Performed by milk.
•	 Vamana yoga:
•	 Madanaphala churna, Vacha churna, and Saindhava in a ratio of 
4:2:1 have been taken.
•	 Madanaphala is the best among all Vamaka dravyas because of 
its Anapayitva property (devoid of complications).
•	 6–8	g	dose	of	Madanaphala pippali churna is given in the present 
clinical study.
•	 Vamanopaga dravyas: Yashtimadhu phanta, Madhu, and Saindhava.
Vamana yoga was	 given	 at	 5	 am–7	 am.	 Process	 was	 continued	 till	
Samyaka shuddhi lakshana was obtained.
Paschata karma
Samsarjana karma was followed as per type of Shuddhi.
METHODOLOGY FOR GROUP B (ATORVASTATIN)
Tablet atorvastatin was given at the dose of 10 mg once a day after 
meals with water for 60 days.
Follow-up
After the completion of the treatment in both the groups, patient was 
advised to visit O.P.D. at interval of 30 days.
Assessment criteria
Objective criteria were mainly assessed on the basis of biochemical 
investigations of lipid profile, body weight, and body mass index (BMI), 
before Vamana Karma and after complete treatment were assessed in 
terms of percentage relief and statistical evaluations (Table 1).
Statistical analysis
The information collected on the basis of above observations was 
subjected to statistical analysis using GraphPad Instat, Software 
version 3.10 and SPSS software. The criteria selected for analysis were 
non-parametric, i.e., grading for objective parameters was taken except 
the ratios which were taken as parametric entities. Hence, “Wilcoxon 
signed-rank	 test”	 within	 the	 group	 and	 “Mann–Whitney	 test”	 for	
intergroup comparison were applied for non-parametric statistical 
improvement analysis, but for the ratios, parametric test applied, 
i.e., paired t-test within the group and unpaired t-test for intergroup 
comparison. In the above statistical tools, the probability value 0.05 is 
considered as statistically significant level.
RESULTS
The study sample consisted of 40 patients, 20 patients in each Group A 
and B, respectively.
Intragroup comparison - Group A
As shown in Tables 2 and 3, the mean value of S. cholesterol reduced 
by 1.80 (76.6%), S. triglyceride reduced by 1.15(79.3%), S. VLDL 
reduced from 0.70 to 0.10 (85.71%), S. LDL reduced by 0.95 (67.85%), 
LDL: HDL reduced by 0.99 (26.80%), total cholesterol: HDL reduced by 
1.59 (25.44%), increase of 0.10 (6.9%) was observed in S. HDL level, 
and BMI reduced from 0.90 to 0.45.
Intragroup comparison - Group B
As shown in Tables 4 and 5, the mean value of S. cholesterol reduced by 
1.85 (78.72%) S. triglyceride reduced by 1.25 (83.3%), S. LDL reduced 
by 1.05 (72.41%), S. VLDL reduced by 0.75 (75%), LDL: HDL reduced 
by 0.89 (26.33%), total cholesterol: HDL reduced by 2.09 (31.79%), fall 
of 0.05 (3.22%) was observed in S. HDL, and BMI reduced from 1.20 to 
1.05.
Intergroup comparison (A and B)
As shown in Tables 6 and 7, intergroup comparison was performed 
between Group A and Group B to compare the efficacy of Vamana Karma 
in comparison to the control drug, i.e., atorvastatin which showed that 
there was no significant difference in all the parameters taken.
S. Cholesterol
Tablet atorvastatin was found more effective in lowering S. cholesterol 
values by 0.05 as compared to results in Group A which was found 
statistically non-significant.
S. Triglyceride
Results obtained in Group B were better as compared to Group A by 
0.10 with statistical non-significance.
S. LDL
Group B showed more effective results by 0.10 with non-significant p 
value.
S. VLDL
Group B showed mild improved result by 0.15 as compared to Group A 
with non-significant p value.
S. HDL
Group A showed much better results in improving S. HDL in comparison 
to negative results obtained in Group B with statistical non-significance.
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LDL: HDL
Group A showed more effective results with statistical non-significance.
Cholesterol: HDL
Group B proved better but with statistical insignificance.
BMI
Group A treatment was found more effective which is statistical 
insignificance.
Overall assessment of therapy
The percentage improvement of S. cholesterol, S. triglyceride, S. LDL, 
and S. VLDL was calculated for assessment as shown in Table 8.
Follow-up study
Follow-up	was	 done	 after	 1	month	 of	 completion	 of	 treatment.	 After	
1 month, all the objective parameters shown slight increment in both the 
groups, but Group A is found to have better follow-up in S. HDL and BMI.
DISCUSSION
Vamana is a safe Panchakarma procedure if undertaken methodically. 
It is a cleansing process that improves appetite, regulates bowel habits, 
and improves sleep pattern. It decreases LDL and serum cholesterol 
level as a part of its Kapha hara	action	[10].	Few	researches	have	shown	
the multisystem effects of Vamana karma without any side effects.
Sangeeta et al. found in a single case study of a 26-year-old male 
patient presented with increased lipid profile in which classical 
Vamana karma was done as the line of management that cholesterol 
and triglycerides had come down after the Vamana procedure [11]. 
According to another study carried out by Gupta et al. on 15 healthy 




180–199	mg/dl Near optimal 1
200–239	mg/dl Borderline high 2





>500 mg/dl Very high 3
LDL
<100 Desirable 0
100–129	mg/dl Near optimal 1
130–159	mg/dl Borderline High 2
160–189	mg/dl High 3




>60 mg/dl Very high 2
HDL
>60 mg/dl Desirable 0
40–60mg/dl Low 1
<40	mg/dl Very low 2
BMI
18.5–25 Normal weight 0
25–30 Overweight 1
30–35 Obese Class I (moderately obese) 2
35–40 Obese Class II (severely obese) 3
>40 Obese Class III (very severely obese) 4
LDL: Low-density lipoproteins, VLDL: Very low-density lipoproteins, 
HDL: High-density lipoproteins, BMI: Body mass index
Table 2: Effect of Vamana karma (Group A) on objective 







Cholesterol 20 2.35 0.55 1.80 76.6
Triglycerides 20 1.45 0.30 1.15 79.3
LDL 20 1.40 0.45 0.95 67.85
VLDL 20 0.70 0.10 0.60 85.71
HDL 20 1.45 1.55 0.10 6.9
BMI 20 0.90 0.45 0.45 50
LDL: Low-density Lipoprotein, VLDL: Very low-density lipoprotein, 
HDL: High-density lipoprotein, BMI: Body mass index, BT: Before treatment, 
AT: After treatment
Table 3: Effect of Vamana karma (Group A) on objective 
parameters of dyslipidemia (paired t-test)
Variables Mean n SD SE
LDL: HDL
BT 3.71 20 0.733 0.164
AT 2.72 20 0.583 0.130
CHO: HDL
BT 6.25 20 1.382 0.309
AT 4.66 20 0.694 0.155
LDL: Low-density lipoprotein, HDL: High-density lipoprotein, 
CHO: Cholesterol, BT: Before treatment, AT: After treatment, 
SD:	Standard	deviation,	SE:	Standard	error	of	the	mean,	N:	Sample	size
Table 4: Effect of tablet atorvastatin (Group B) on objective 







Cholesterol 20 2.35 0.50 1.85 78.72
Triglycerides 20 1.50 0.25 1.25 83.3
LDL 20 1.45 0.40 1.05 72.41
VLDL 20 1.00 0.25 0.75 75
HDL 20 1.55 1.50 -0.05 -3.22
BMI 20 1.20 1.05 0.15 12.5
LDL: Low-density lipoprotein, VLDL: Very low-density lipoprotein, 
HDL: High-density lipoprotein, BMI: Body mass index, BT: Before treatment, 
AT: After treatment
Table 5: Effect of tablet atorvastatin (Group B) on objective 
parameters of dyslipidemia (paired t-test)
LDL: HDL Mean n SD SE
BT 3.40 20 0.841 0.188
AT 2.51 20 0.593 0.133
CHO: HDL
BT 6.58 20 1.325 0.296
AT 4.49 20 1.000 0.224
LDL: Low-density lipoprotein, HDL: High-density lipoprotein, 
CHO: Cholesterol, BT: Before treatment, AT: After treatment, 
SD:	Standard	deviation,	SE:	Standard	error	of	the	mean,	N:	Sample	size
Table 6: Intergroup comparison (unpaired t-test)
Variables Mean n SD SE Result
LDL: HDL
Group a 0.995 20 0.558 0.125 NS
Group B 0.896 20 0.946 0.212
CHO: HDL
Group A 1.590 20 1.057 0.236 NS
Group B 2.092 20 0.987 0.221
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volunteers to evaluate the physiological and biochemical changes 
in Vamana karma, it was found that there was decrease in the LDL 
and cholesterol during as well as after the procedure [10]. In a study 
performed by Sharma et al. in which Vamana karma done with 
Dhamargava kalpa followed by Lekhaneeya ghana vati as Shamana 
aushadhi has given statistically significant results in lowering lipid 
levels. In different parameters of lipid profile, the mean reduction 
of serum cholesterol and serum triglycerides showed better results 
statistically [12].
This study is an attempt to prove the efficacy of Ayurvedic biopurificatory 
measure, i.e., Vamana karma in comparison to the prevailing allopathic 
treatment, i.e. atorvastatin as a control group for dyslipidemia. Thus, 
the lipid-lowering action of Vamana karma occurs mainly through two 
pathways -
1. By eliminating out excess circulating lipids (Kapha Dosha) - Vamana 
eliminates	specifically	Kapha Dosha which belongs to MedoDhatu, 
thus having its direct effect on fat tissue and thus decreasing lipid 
levels.
2. By correcting the lipoprotein metabolism in liver - Vamana also has 
moderate action on bringing Pitta to a state of normalcy. Pitta is 
responsible for all the digestion (Paka) and metabolism (Parinama) 
in the body and dyslipidemia is a disorder of deranged lipid 
metabolism, i.e., a disturbed state of Pitta. Hence, by controlling the 
vitiated state of Pitta, Vamana corrects the malproduction of lipids 
and	brings	a	state	of	equilibrium.	Furthermore,	the	main	seat	of	Pitta 
is Yakrita (liver) which controls the formation of lipids and Vamana 
karma having direct effect on liver functioning controls the whole 
metabolism of lipid formation and excretion.
CONCLUSION
Vamana karma is highly effective in correcting serum lipid profile 
except HDL and VLDL but have better effect than the standard drug 
in both of them. Vamana karma can be used for the effective and safe 
management of dyslipidemia.
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Table 7: Intergroup comparison (Mann–Whitney test)
Variables Group n Mean rank Sum of ranks Mann–Whitney U result
Cholesterol Group A 20 1.800 406.5 196.5 NS
Group B 20 1.850 413.5
Triglycerides Group A 20 1.150 394.5 184.5 NS
Group B 20 1.250 425.5
LDL Group A 20 0.950 395.5 185.5 NS
Group B 20 1.050 424.5
VLDL Group A 20 0.6000 395 185 NS
Group B 20 0.7500 425
HDL Group A 20 0.1000 437.50 172.5 NS
Group B 20 −0.0500 382.50
BMI Group A 20 0.4500 465.5 144.5 NS
Group B 20 0.1500 354.5
LDL: Low-density lipoprotein, VLDL: Very low-density lipoprotein, HDL: High-density lipoprotein, BMI: Body mass index, BT: Before treatment, AT: After treatment, 
NS: Non-significant
Table 8: Overall assessment of the therapy
Overall effect Group A Group B
Frequency (%) Frequency (%)
Complete resolution 1 (5) 0 (0)
Marked improvement 4 (20) 2 (10)
Moderate improvement 11 (55) 12 (60)
Mild improvement 4 (20) 6 (30
No change 0 (0) 0 (0)
Total 20 (100) 20 (100)
